Calithera Biosciences Past Earnings Performance
Past criteria checks 0/6
Calithera Biosciences's earnings have been declining at an average annual rate of -11.1%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 54.1% per year.
Key information
-11.1%
Earnings growth rate
6.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -54.1% |
| Return on equity | -194.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Calithera Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -21 | 14 | 0 |
| 30 Sep 22 | 0 | -84 | 15 | 51 |
| 30 Jun 22 | 7 | -85 | 19 | 51 |
| 31 Mar 22 | 10 | -107 | 19 | 51 |
| 31 Dec 21 | 10 | -115 | 21 | 51 |
| 30 Sep 21 | 10 | -68 | 22 | 0 |
| 30 Jun 21 | 3 | -80 | 20 | 0 |
| 31 Mar 21 | 0 | -86 | 21 | 0 |
| 31 Dec 20 | 0 | -90 | 20 | 0 |
| 30 Sep 20 | 0 | -89 | 19 | 0 |
| 30 Jun 20 | 0 | -87 | 18 | 0 |
| 31 Mar 20 | 0 | -91 | 17 | 0 |
| 31 Dec 19 | 0 | -90 | 17 | 0 |
| 30 Sep 19 | 0 | -88 | 15 | 0 |
| 30 Jun 19 | 0 | -86 | 14 | 0 |
| 31 Mar 19 | 17 | -65 | 14 | 0 |
| 31 Dec 18 | 22 | -55 | 13 | 0 |
| 30 Sep 18 | 30 | -46 | 13 | 0 |
| 30 Jun 18 | 37 | -33 | 13 | 0 |
| 31 Mar 18 | 27 | -35 | 13 | 0 |
| 31 Dec 17 | 26 | -28 | 13 | 0 |
| 30 Sep 17 | 19 | -26 | 12 | 0 |
| 30 Jun 17 | 11 | -29 | 11 | 0 |
| 31 Mar 17 | 4 | -34 | 11 | 0 |
| 31 Dec 16 | 0 | -38 | 11 | 0 |
| 30 Sep 16 | 0 | -37 | 10 | 6 |
Quality Earnings: 2CB0 is currently unprofitable.
Growing Profit Margin: 2CB0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2CB0 is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.
Accelerating Growth: Unable to compare 2CB0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2CB0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 2CB0 has a negative Return on Equity (-194.44%), as it is currently unprofitable.